Research record

The scientific record

Peer-reviewed publications and registered clinical studies across peptide science. Records are retrieved from independent public databases and link directly to their original source.

Publications indexed

Clinical studies

23 Oct 2026

Records updated

Latest publications

124 matching records on PubMed

PubMedRapid communications in mass spectrometry : RCM2026 Dec 15

Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis

Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, Dos Santos PF + 3 more

PMID 42745421

View on PubMed

PubMedCardiology in review2026 Nov-Dec 01

The First Triple Agonist for Antiobesity: Retatrutide

Tetelbaun L, Mullally JA, Frishman WH

Review

PMID 39724554

View on PubMed

PubMedThe New England journal of medicine2026 Oct 21

Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea

Grunstein RR, Somers VK, Azarbarzin A, Malhotra A + 9 more

PMID 42904878

View on PubMed

PubMedThe Journal of clinical endocrinology and metabolism2026 Oct 16

Medical treatments for obesity: what does the future have in store?

Bassatne A, Rizo I

Review

PMID 42444567

View on PubMed

PubMedAesthetic surgery journal2026 Oct 15

Do Glucagon-Like Peptide-1 Receptor Agonists Sabotage Fat Grafts?: A Scoping Review of Glucagon-Like Peptide-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer

Chalhoub X, Ng ZY

Scoping Review

PMID 42219269

View on PubMed

PubMedActa diabetologica2026 Oct 14

GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?

Leite Júnior AC, Ribeiro Junior HL

Review

PMID 42873315

View on PubMed

PubMedJournal of chromatography. A2026 Oct 11

Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application

Tong LH, Leung KK, Hung CT

PMID 42603384

View on PubMed

PubMedEuropean journal of pharmacology2026 Oct 8

GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases

Koceva E, Moll GN

Review

PMID 42849689

View on PubMed

PubMedBMJ case reports2026 Oct 7

Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide

Buzzi RM, Huber LC

Case Reports

PMID 42843917

View on PubMed

PubMedNutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition2026 Oct

Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

Singhani V, Ehsan M, Valencia S, Nadeem A + 3 more

Review

PMID 42808923

View on PubMed

PubMedAnnals of internal medicine2026 Oct

Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review

Moiz A, Filion KB, Samuels AE, Tsoukas MA + 3 more

Systematic Review
Review

PMID 42673585

View on PubMed

PubMedInternational journal of molecular sciences2026 Sep 30

GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review

Popa E, Popa AE, Poroch V, Schreiner TG + 7 more

Review

PMID 42883986

View on PubMed

Clinical studies

3 registered records on ClinicalTrials.gov

ClinicalTrials.govNCT07165028

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Phase3
Recruiting
Interventional
Drug

Sponsor: Eli Lilly and Company
Enrollment: 4,500 participants
Study status: Recruiting
Last updated: 8 Oct 2026

Source: ClinicalTrials.gov

View on ClinicalTrials.gov

ClinicalTrials.govNCT06662383

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Phase3
Active Not Recruiting
Interventional
Drug

Sponsor: Eli Lilly and Company
Enrollment: 800 participants
Study status: Active Not Recruiting
Last updated: 20 Jul 2026

Source: ClinicalTrials.gov

View on ClinicalTrials.gov

ClinicalTrials.govNCT07226947

Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment

Recruiting
Interventional
Device
Behavioral

Sponsor: Massachusetts General Hospital
Enrollment: 100 participants
Study status: Recruiting
Last updated: 30 Dec 2025

Source: ClinicalTrials.gov

View on ClinicalTrials.gov

About the research library

Research records displayed within the Avion Science Research Library are retrieved from independent public scientific databases including PubMed and ClinicalTrials.gov. Inclusion within this library does not imply endorsement by Avion Science and does not establish the safety, efficacy or intended use of any Avion Science product. Information is provided for scientific and educational purposes and users should refer to the original source for complete study information.

PubMed and ClinicalTrials.gov are independent third-party resources and are not affiliated with Avion Science.